Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. The company's products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro and lispro mix 75/25 injection; Prandilin 25, an insulin lispro injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection. It also offers GanleePen, an insulin injection device; GanleeFine, an insulin pen needle; and medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.